Skip to main content
PEPTIDE / PORTAL
OverviewVendorsScienceReference
Liraglutide product
Metabolic Pathway Research ·

LiraglutideVictoza; Saxenda

GLP-1 receptor agonist research

Also known as Victoza; Saxenda.

6 papers·FDA-approved·COA Unverified·0 saved
Scientific name
Victoza; Saxenda
Category
Metabolic Pathway Research
US status
Research only

Evidence last verified May 9, 2026

3 results
ProductVendorSizePrice$/mgPurityCOAStock
GLP-1.2
CPure Rawz
2mg$23.29$11.65/mg99%
Finnrick mixed
Visit
GLP-1.2
CPure Rawz
5mg$61.86$12.37/mg99%
Finnrick mixed
Visit
Liraglutide
BPlatinum Peptides
5mg$99.95$19.99/mg
None
Visit
GLP-1
CPure Rawz
5mg$129.99$26/mg99%
Finnrick mixed
Visit
GLP-1
CPure Rawz
10mg$249.99$25/mg99%
Finnrick mixed
Visit

Scientific Details

Scientific Research
YearTitle / JournalTypeCites
2026
Liraglutide in mild to moderate Alzheimer disease: a phase 2b clinical trial
Nature Medicine
Clinical Trial0
2026
Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD
Clinical Obesity
Clinical Trial0
2026
Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass
Diabetes Research and Clinical Practice
Clinical Trial0
2026
Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis
Diabetes, Obesity & Metabolism
Clinical Trial0
2025
Combination metformin and liraglutide in PCOS: clinical efficacy in women and preclinical insights from gut microbiome modulation in rats
Frontiers in Endocrinology
Clinical Trial0
2016
Marso 2016 — LEADER Liraglutide Cardiovascular Outcomes
New England Journal of Medicine
RCT6500

Showing 6 of 6 papers

Reference

Regulatory Status
USResearch only
EUNot approved
UKResearch only
AUResearch only

Regulatory status may change. Always verify current regulations in your jurisdiction before purchase.